Central precocious puberty is a medical condition characterized by the early onset of the normal sexual development process in both girls and boys. It occurs when the initiation of sexual development happens earlier than the typical age range. There’s no underlying medical problem or identifiable reason for early puberty.
Sizing and Forecast
The central precocious puberty market size has grown strongly in recent years. It will grow from $1.81 billion in 2023 to $1.97 billion in 2024 at a compound annual growth rate (CAGR) of 8.9%. The growth in the historic period can be attributed to increased prevalence of central precocious puberty, improvements in treatment approaches, impact of environmental factors, increased pediatric endocrinology services, parental concerns and seeking medical attention, patient advocacy efforts..
The central precocious puberty market size is expected to see strong growth in the next few years. It will grow to $2.74 billion in 2028 at a compound annual growth rate (CAGR) of 8.6%. The growth in the forecast period can be attributed to pediatric healthcare integration, shift towards personalized medicine, parental education and awareness programs, development of longer-acting treatment options, early diagnosis and intervention.. Major trends in the forecast period include long-acting formulations, patient-centric approaches, telehealth and remote monitoring, individualized treatment approaches, collaborative care models, digital health tools for monitoring..
Order your report now for swift delivery, visit the link:
https://www.thebusinessresearchcompany.com/report/central-precocious-puberty-global-market-report
Segmentation & Regional Insights
The central precocious puberty market covered in this report is segmented –
1) By Drug: Leuprolide Acetate, Triptorelin, Histrelin Acetate, Nafarelin
2) By Route Of Administration: Parenteral, Subcutaneous, Intramuscular, Other Routes Of Administrations
3) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy
4) By End-Users: Hospitals, Specialty Clinics, Homecare, Other End-Users
North America was the largest region in the central precocious puberty market in 2023. The regions covered in the central precocious puberty market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Intrigued to explore the contents? Secure your hands-on a free sample copy of the report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=13184&type=smp
Major Driver Impacting Market Growth
An increase in research and development activities is expected to propel the growth of the central precocious puberty market going forward. Research and development activities refer to various processes and activities organizations undertake to create new knowledge, products, services, or procedures or enhance existing ones. Research and development (R&D) activities play a crucial role in central precocious puberty (CPP) by contributing to a better understanding of the condition, improving diagnosis and treatment options, and enhancing the overall care of individuals suffering from central precocious puberty. For instance, in August 2023, according to Eurostat, a Luxembourg-based non-profit organization, the European government earmarked approximately $126,153 million (€117,368 million) for research and development (R&D) in 2022, marking a 5.4% rise compared to the $119,730 million (€111,393 million) allocated in 2021. Furthermore, in January 2022, according to the Regulatory Affairs Professionals Society, a US-based regulatory organization of healthcare and related products, overall, 37 drugs (74%) in 2021 were approved by the US Food and Drug Administration (FDA) through at least one expedited pathway, an increase from 68% of novel drugs in 2020. Therefore, the increase in the number of research and development activities is driving the growth of the central precocious puberty market.
Key Industry Players
Major companies operating in the central precocious puberty market report are Cipla Limited, Cigna Group, Pfizer Inc., AbbVie Inc., Sanofi S.A., AstraZeneca PLC, Abbott Laboratories, Molina Healthcare Inc., Sun Pharmaceutical Industries Ltd., Ipsen Ltd., Ferring Pharmaceuticals Private Limited, Endo Pharmaceuticals Inc., Amneal Pharmaceuticals Inc., Piramal Enterprises Limited , Livzon Pharmaceutical Group Inc., Salvavidas Pharmaceutical Pvt. Ltd., Actiza Pharmaceutical Private Limited, The Bachem Group, Arbor Pharmaceuticals LLC, Genentech Inc., Antares Pharma Inc., Tolmar Pharmaceuticals Inc., Debiopharm Group, AmbioPharm Inc., Foresee Pharmaceuticals Co. Ltd., Manus Aktteva Biopharma LLP, Midas Pharma GmbH, LGM Pharma LLC, Varian Pharmed Group, Shenzhen JYMed Technology Co. Ltd.
The central precocious puberty market report table of contents includes:
1. Executive Summary
2. Market Characteristics
3. Market Trends And Strategies
4. Impact Of COVID-19
5. Market Size And Growth
6. Segmentation
7. Regional And Country Analysis
.
.
.
27. Competitive Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis
Explore the trending research reports from TBRC:
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
